ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Recombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001

Its studies are mostly in Glioma · Breast Neoplasms · Adenoviridae Infections, led by Beijing Bio-Targeting Therapeutics Technology.

Drug pageRecombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jan 2, 20253 company-led studies, 2 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Bio-Targeting Therapeutics Technology32 open or runningphase 2since Jan 2, 2025Nov 27, 2023Jul 31, 2027phase 2 · NCT06763965

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2023First study: phase 1 study in Adenoviridae InfectionsFirst studyNCT06215846 · 12 planned · China
  2. Jan 2, 2025Phase 2 study in GliomaNCT06763965 · 30 planned · China
  3. Aug 25, 2025Phase 1 study in Locally Advanced Breast Cancer (LABC)NCT07150767 · China

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in GliomaNCT06763965

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07150767Locally Advanced Breast Cancer (LABC) · China1WithdrawnMar 26, 20270
NCT06763965Glioma · China2By invitationJul 31, 202730
NCT06215846Adenoviridae Infections · China1By invitationMay 30, 202612

How it is read

Names in the registry

  • “BioTTT001 injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.